RegulationPriority Review (United States), Fast Track (United States), Orphan Drug (United States), Qualified Infectious Disease Product (United States), Orphan Drug (European Union)

Structure/Sequence

Molecular FormulaC50H75N5O11

InChIKeyWKIRTJACGBEXBZ-FQGZCCSZSA-N

CAS Registry1965291-08-0

Clinical Trials associated with Ibrexafungerp Citrate

NCT06954493

/ CompletedPhase 1

Phase 1, Open-Label Pharmacokinetic Study in Healthy Lactating Women After Two Oral Doses of Ibrexafungerp Administered on a Single Day

This is a pharmacokinetic evaluation of lactating women after receiving two doses of Ibrexafungerp. The study population included healthy lactating females who were at least 10 days postpartum with a fully established milk supply and were between the ages of 18 and 50 years at the time of screening

Start Date12 Jul 2023

Sponsor / Collaborator

SCYNEXIS, Inc.

CTR20223058

/ SuspendedPhase 3

一项在念珠菌血症和/或侵袭性念珠菌病患者中比较两项治疗方案（静脉注射棘白菌素后口服Ibrexafungerp 和静脉注射棘白菌素后口服氟康唑）的III 期、多中心、前瞻性、随机、双盲研究（MARIO）

[Translation] A phase III, multicenter, prospective, randomized, double-blind study comparing two treatment regimens (IV echinocandin followed by oral ibrexafungerp vs. IV echinocandin followed by oral fluconazole) in patients with candidemia and/or invasive candidiasis (MARIO)

主要研究目的：在念珠菌血症和/或侵袭性念珠菌病患者中，评估IV 棘白菌素后口服Ibrexafungerp 第30 天的全因死亡率（All Cause Moritality, ACM）非劣效于IV 棘白菌素后口服氟康唑的治疗方案；关键次要研究目的：在念珠菌血症和/或侵袭性念珠菌病患者中，评估IV 棘白菌素后口服Ibrexafungerp 第14 天的总体应答率（经数据审查委员会 [Data Review Committee, DRC] 判定的临床、影像学和真菌学方面的综合应答）非劣效于IV 棘白菌素后口服氟康唑的治疗方案；其他次要目的：根据第30天和抗真菌治疗结束时的总体应答、临床应答、真菌学应答、无复发、患者存活且真菌学清除指标来评估有效性；评估IV棘白菌素后口服Ibrexafungerp治疗的安全性；评估Ibrexafungerp的药代动力学（PK）特征。

[Translation]

The primary study objective was to evaluate the non-inferiority of oral ibrexafungerp after IV echinocandin to oral fluconazole in terms of all-cause mortality (ACM) at day 30 in patients with candidemia and/or invasive candidiasis. The key secondary study objective was to evaluate the non-inferiority of oral ibrexafungerp after IV echinocandin to oral fluconazole at day 14 in patients with candidemia and/or invasive candidiasis (composite clinical, radiological, and mycological responses as assessed by the Data Review Committee [DRC]). Other secondary objectives were to evaluate the efficacy based on overall response, clinical response, mycological response, freedom from relapse, patient survival, and fungal clearance at day 30 and at the end of antifungal treatment; to evaluate the safety of oral ibrexafungerp after IV echinocandin; and to evaluate the pharmacokinetic (PK) characteristics of ibrexafungerp.

Start Date18 Mar 2023

Sponsor / Collaborator

SCYNEXIS, Inc.

[+1]

ISRCTN51111674

/ RecruitingPhase 1

A phase I, open-label, single-centre study to evaluate the absorption, distribution, metabolism and excretion (ADME) of oral [14C]-ibrexafungerp in healthy male subjects after repeat dosing

Start Date15 Dec 2022

Sponsor / Collaborator-

100 Clinical Results associated with Ibrexafungerp Citrate

100 Translational Medicine associated with Ibrexafungerp Citrate

100 Patents (Medical) associated with Ibrexafungerp Citrate

145

Literatures (Medical) associated with Ibrexafungerp Citrate

01 Dec 2025·Journal of Global Antimicrobial Resistance

In vitro evaluation of Ibrexafungerp against clinical and environmental isolates of cryptococcus neoformans and cryptococcus gattii

Letter

Author: Firacative, Carolina ; Ceballos-Garzon, Andrés

01 Oct 2025·Journal of Lower Genital Tract Disease

Vulvovaginal Candidiasis Caused by Candida krusei (Pichia kudriavzevii), Still a Formidable Challenge

Article

Author: Vempati, Yogitha Sai ; Sobel, Jack D

Objectives:

In recent years, the prevalence of non-albicans Candida vulvovaginitis has risen with Candida glabrata and Candida krusei (Pichia kudriavzevii) being prominent contributors. Candida krusei poses a significant challenge due to its intrinsic resistance to fluconazole, both in vitro and clinically. Practitioners face difficulties managing patients with chronic symptomatic vulvovaginal candidiasis who fail to respond to multiple courses of oral fluconazole and over the counter (OTC) antifungals.

Methods:

The authors analyzed retrospectively a cohort of women who had chronic vulvovaginal symptoms seen in their vaginitis clinic between 2017 and 2024. Clinical charts of 11 patients with positive C. krusei vaginal fungal isolates were reviewed. Antifungal susceptibility of isolates was assessed, and treatments, including novel antifungal agents oteseconazole and ibrexafungerp, were evaluated for their efficacy in symptom control.

Results:

In 10 of 11 patients, symptoms were attributed to C. krusei vaginitis, while in 1 patient, C. krusei was found to be an innocent bystander. Candida krusei vaginal isolates in vitro susceptibility testing demonstrated resistance not only limited to fluconazole but also to miconazole, ketoconazole, and other azole agents. Although itraconazole exhibited in vitro activity, treatment often failed to achieve clinical or mycologic remission. Despite the availability of new antifungal agents, vaginal boric acid emerged as the initial if not definitive treatment method of choice.

Conclusion:

Determining the antifungal susceptibility profile of C. krusei vaginal isolates may be required in selecting effective antifungal treatment of refractory vaginitis due to non-albicans Candida (NAC).

01 Sep 2025·CTS-Clinical and Translational Science

Ibrexafungerp: Mechanism of Action, Clinical, and Translational Science

Review

Author: Woodahl, Erica L. ; Dupuis, Lauren N. ; Killam, Shayna R. ; Walley, Adelynne H.

ABSTRACT:

Ibrexafungerp is a first‐in‐class triterpenoid antifungal that targets β‐(1,3)‐glucan synthase in fungal cell wall development. It is indicated for vulvovaginal candidiasis (VVC) and recurrent vulvovaginal candidiasis (RVVC) in adult and post‐menarchal pediatric females. The drug was approved in 2021 and 2022 for VVC and RVVC, respectively. Research is ongoing to evaluate the safety of ibrexafungerp in pregnancy and lactation as well as to explore intravenous and oral formulations for invasive candidiasis and invasive aspergillosis. Ibrexafungerp binds and inhibits β‐(1,3)‐glucan synthase that is essential for the synthesis of β‐(1,3)‐D‐glucan, a key polymer in the fungal cell wall, leading to cell lysis and death. This mechanism of action varies from that of the current VVC therapy, fluconazole, which makes ibrexafungerp a primary candidate for treating fluconazole‐resistant patient cases. The drug is distributed into vaginal tissue at higher concentrations and has increased efficacy at lower pH compared to fluconazole, indicating a therapeutic advantage for VVC. Ibrexafungerp was generally well‐tolerated in most participants throughout clinical trials. The most commonly reported treatment‐emergent adverse events were headache, dizziness, and gastrointestinal‐related effects. The efficacy of ibrexafungerp was found to be comparable to fluconazole and superior to placebo as seen in key clinical trials: DOVE (NCT03253094) and VANISH303 (NCT03734991). We reviewed the regulatory approval process of ibrexafungerp, including key clinical trials and in‐depth analyses of pivotal studies related to the drug's clinical efficacy and safety. Additionally, we reviewed the drug's unique mechanism of action and the pharmacokinetic and pharmacodynamic characteristics essential for its use in VVC and RVVC.

134

News (Medical) associated with Ibrexafungerp Citrate

15 Oct 2025

·www.fiercepharma.com

GSK makes nice with antifungal partner Scynexis with $22M payment to resolve trial dispute

In addition to its $22 million payout from GSK, Scynexis will collect another $2.3 million related to trial wind-down activities. Brexafemme (ibrexafungerp) partners GSK and Scynexis have worked out their quarrel related to a clinical trial that was previously put on hold, leaving Scynexis with a $22 million payout.Per the resolution, Scynexis will wind down its phase 3 MARIO study of Brexafemme in invasive candidiasis, the company said in an Oct. 15 press release. Besides the $22 million sum, the company stands to receive an additional $2.3 million related to trial wind-down activities, Scynexis said.Scynexis will not receive any further milestone payments from GSK in relation to the MARIO study.GSK is still on board with its Scynexis collaboration and plans to commercialize Brexafemme in its approved indications of vulvovaginal candidiasis (VVC) and refractory vulvovaginal candidiasis (rVVC), according to Scynexis. After Scynexis transfers the drug’s regulatory application to GSK by the end of this year, the British company hopes to begin discussions with the FDA on a relaunch of the medicine.“While disappointed that the MARIO study will not continue, we’re pleased to have resolved this disagreement with GSK and that it remains committed to relaunching Brexafemme,” Scynexis CEO David Angulo, M.D., said in the release.GSK and Scynexis shook hands on a Brexafemme licensing deal in early 2023. Later that year, GSK found that the equipment used to make the drug was also used to produce a beta-lactam substance, which can trigger allergies in some people. Scynexis then recalled the drug due to the potential for cross-contamination.When the FDA lifted a clinical trial hold after 19 months this May, Scynexis quickly moved to resume the delayed study. GSK, for its part, wanted its partner to terminate the trial. GSK’s objections were still in play when Scynexis began dosing patients in the re-enrolled study, triggering a $10 million milestone payment under the original contract. GSK disputed the milestone but said it remained committed to marketing the drug.Brexafemme was approved in 2021 for VVC, bringing a new class of antifungal drugs to the indication. GSK paid Scynexis $90 million upfront to get in on the drug, but later cut down its milestone obligations as part of a 2024 deal amendment.

Phase 3License out/inDrug Approval

15 Oct 2025

·www.globenewswire.com

SCYNEXIS and GSK Resolve Their Disagreement Related to the Restart of the Phase 3 MARIO Study

SCYNEXIS to receive a $22 million payment as part of the resolution related to the restart of the Phase 3 MARIO study on invasive candidiasisScynexis will promptly wind-down and terminate the MARIO studyThe payment from GSK, combined with cash in hand and removal of future MARIO expenditures, extends the company’s cash runway to more than two yearsGSK remains committed to the commercialization of BREXAFEMME (ibrexafungerp tablets) JERSEY CITY, N.J., Oct. 15, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it will receive a $22 million payment from GlaxoSmithKline Intellectual Property (No. 3) Limited (GSK) as part of a resolution of the disagreement with GSK related to the restart of the Phase 3 MARIO study on invasive candidiasis. SCYNEXIS will not receive additional milestone payments from GSK associated with the MARIO study. SCYNEXIS will promptly commence appropriate wind-down activities associated with its termination and will receive an additional $2.3M payment in connection with these activities. GSK has also reiterated its commitment to continued collaboration with SCYNEXIS regarding other aspects of the GSK License Agreement, including with respect to the commercialization of BREXAFEMME (ibrexafungerp tablets) for the vulvovaginal candidiasis (VVC) and refractory vulvovaginal candidiasis (rVVC) indications. SCYNEXIS continues to progress the transfer of the BREXAFEMME NDA to GSK by the end of 2025. GSK anticipates being able to initiate regulatory interactions with the U.S. Food and Drug Administration in 2026 to discuss the relaunch of BREXAFEMME for VVC and rVVC in the U.S. market. “While disappointed that the MARIO study will not continue, we’re pleased to have resolved this disagreement with GSK and that it remains committed to relaunching BREXAFEMME. SCYNEXIS remains committed to developing novel antifungal solutions, including SCY-247, its second-generation triterpenoid antifungal under development for the treatment and prevention of invasive fungal infections with the potential to provide the therapeutic advantages of both an oral and IV formulation,” said David Angulo, M.D., President and Chief Executive Officer. “We want to thank all of the patients who participated in the MARIO study and the investigators for their continued support toward finding new antifungal agents in areas of significant unmet need.” About SCYNEXISSCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. SCYNEXIS is developing the company’s proprietary antifungal platform “fungerps.” Ibrexafungerp, the first representative of this novel class, has been licensed to GSK. The U.S. Food and Drug Administration (FDA) approved BREXAFEMME® (ibrexafungerp tablets) in June 2021, for its first indication in vulvovaginal candidiasis (VVC), followed by a second indication in November 2022, for reduction in the incidence of recurrent VVC. Additional antifungal assets from this novel class are currently in clinical, pre-clinical and discovery phases, including the compound SCY-247. For more information, visit www.scynexis.com. Forward-Looking StatementsStatements contained in this press release regarding expected future events or results are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements regarding: any advantages of SCY-247 over existing antifungals, continued development of SCY-247, and the Company’s cash runway. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks inherent in regulatory and other costs in developing products. These and other risks are described more fully in SCYNEXIS' filings with the Securities and Exchange Commission, including without limitation, its most recent Annual Report on Form 10-K filed on March 12, 2025, including under the caption "Risk Factors." All forward-looking statements contained in this press release speak only as of the date on which they were made. SCYNEXIS undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. CONTACT: Investor RelationsIrina KofflerLifeSci AdvisorsTel: 917-734-7387ikoffler@lifesciadvisors.com

License out/inPhase 3Drug ApprovalNDA

15 Oct 2025

·endpoints.news

Boehringer makes an ADC deal with AimedBio; EyePoint’s $150M stock sale

Plus, news about Scynexis, Step Pharma, Eradivir, J&J, Omnix Medical and Mission Therapeutics: 💼 Boehringer Ingelheim does another cancer deal: The German drugmaker will pay up to $991 million to Seoul-based AimedBio for access to an antibody-drug conjugate that is slated to enter Phase 1 next year. The companies didn’t disclose any details about the ADC, other than saying it’s for cancer. Boehringer has done a series of deals in recent years to boost its oncology footprint, including with Nerio Therapeutics , Tessellate Bio and Accent Therapeutics. — Kyle LaHucik 👁️ EyePoint Pharmaceuticals’ $150M offering: The company is selling 11 million shares for $12.00 apiece to help progress Duravyu as a treatment for wet age-related macular degeneration and diabetic macular edema. — Jaimy Lee 💰 Scynexis gets $22M from GSK, to terminate Phase 3 trial: The biotech said the payment resolves a dispute with the British drugmaker, and it will now wind down the late-stage study testing SCY-247 in invasive candidiasis. The companies will continue to work together on vaginal infection drug Brexafemme, which was pulled from the market in 2023 over contamination concerns. The payment extends Scynexis’ cash runway for two years. Its stock price $SCYX was up 6% at market open on Wednesday. — Jaimy Lee 💶 Step Pharma’s €38M Series C: The money will help the French biotech continue work on its early-phase CTPS1 inhibitor called dencatistat in certain blood cancers and solid tumors. The raise was led by new investor V-Bio Ventures, with existing investors Bpifrance, Hadean Ventures, Inserm Transfert Initiative, Kurma Partners, Pontifax Venture Capital and Sunstone Life Science Ventures also pitching in. The biotech raised €35 million in 2021. — Reynald Castaneda Hello Victoria Ward , Endpoints is fielding its next Pulse Poll — a one-minute check-in on how artificial intelligence is reshaping biopharma. Results are confidential and will feed into our coverage of AI's real-world impact. Hello Victoria Ward , Endpoints is fielding its next Pulse Poll — a one-minute check-in on how artificial intelligence is reshaping biopharma. Results are confidential and will feed into our coverage of AI's real-world impact. Hello Victoria Ward , Endpoints is fielding its next Pulse Poll — a one-minute check-in on how artificial intelligence is reshaping biopharma. Results are confidential and will feed into our coverage of AI's real-world impact. Hello Victoria Ward , Endpoints is fielding its next Pulse Poll — a one-minute check-in on how artificial intelligence is reshaping biopharma. Results are confidential and will feed into our coverage of AI's real-world impact. Hello Victoria Ward , Endpoints is fielding its next Pulse Poll — a one-minute check-in on how artificial intelligence is reshaping biopharma. Results are confidential and will feed into our coverage of AI's real-world impact. Hello Victoria Ward , Endpoints is fielding its next Pulse Poll — a one-minute check-in on how artificial intelligence is reshaping biopharma. Results are confidential and will feed into our coverage of AI's real-world impact. Hello Victoria Ward , Endpoints is fielding its next Pulse Poll — a one-minute check-in on how artificial intelligence is reshaping biopharma. Results are confidential and will feed into our coverage of AI's real-world impact. Hello Victoria Ward , Endpoints is fielding its next Pulse Poll — a one-minute check-in on how artificial intelligence is reshaping biopharma. Results are confidential and will feed into our coverage of AI's real-world impact. 🌡 Eradivir’s flu candidate clears Phase 2a trial: Influenza patients treated with a 300 mg dose of the biotech’s EV25 demonstrated a “significant reduction” in symptom duration and severity compared with placebo. Furthermore, more than 80% of placebo patients went on to develop lower respiratory tract infection versus about 35% of treated patients. Eradivir said it is planning to start a large Phase 2b study in the US and Europe during next year’s flu season. — Ayisha Sharma ⚠️ Johnson & Johnson’s Carvykti gets black box warning for intestinal inflammation: The FDA added the warning for immune effector cell-associated enterocolitis following cases reported in clinical trials and post-marketing data. The agency noted that some cases resulted in death from gut perforation and sepsis. The multiple myeloma CAR-T therapy’s label was also updated with overall survival benefit. J&J and Legend Biotech developed Carvykti. — Lei Lei Wu 💰 Omnix Medical’s $25M Series C: The Israeli company said the round was co-led by Harel Insurance & Finance and the EIC Fund. It’s developing a drug called OMN6 to treat infections caused by Acinetobacter baumannii and other Gram-negative bacteria. — Jaimy Lee 💸 Mission Therapeutics corrals $13.3M: The Cambridge, UK-based drugmaker will use the proceeds to run a Phase 1b study to investigate its lead asset, codenamed MTX325, for Parkinson’s disease. The study is set to start in the first half of 2026. Its latest raise is from existing investors. — Reynald Castaneda

Phase 2Phase 1

100 Deals associated with Ibrexafungerp Citrate

External Link

KEGG	Wiki	ATC	Drug Bank
D11544	-	J02AX	DB12471

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Candidiasis, Vulvovaginal	United States	SCYNEXIS, Inc.	01 Jun 2021

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Candida Auris Infection	Phase 3	United States	SCYNEXIS, Inc.	15 Nov 2017
Candida Auris Infection	Phase 3	India	SCYNEXIS, Inc.	15 Nov 2017
Candida Auris Infection	Phase 3	Pakistan	SCYNEXIS, Inc.	15 Nov 2017
Candida Auris Infection	Phase 3	South Africa	SCYNEXIS, Inc.	15 Nov 2017
Candidemia	Phase 3	United States	SCYNEXIS, Inc.	15 Nov 2017
Candidemia	Phase 3	India	SCYNEXIS, Inc.	15 Nov 2017
Candidemia	Phase 3	Pakistan	SCYNEXIS, Inc.	15 Nov 2017
Candidemia	Phase 3	South Africa	SCYNEXIS, Inc.	15 Nov 2017
Aspergillosis, Allergic Bronchopulmonary	Phase 3	United States	SCYNEXIS, Inc.	01 Apr 2017
Aspergillosis, Allergic Bronchopulmonary	Phase 3	Austria	SCYNEXIS, Inc.	01 Apr 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06954493 (CTgov)	Phase 1	Candidiasis, Vulvovaginal	5	Ibrexafungerp	iedmjbkkql(cuaxxjftgk) = adpnegbpnc whuzcwvgau (tnntamktlo, iokficlnnn - tfjmhpdxrx) View more	-	08 Aug 2025
NCT03059992 (FURI, CTgov)	Phase 3	Candidiasis, Vulvovaginal \| Coccidioidomycosis \| Histoplasmosis ... View more	233	Ibrexafungerp	ztchuegfrd(bsxsoxpqyx) = axcfxybucc crtofqrdwz (lqyvzxwrrs, dqrrrjpfav - isjwczrqcg) View more	-	20 Nov 2024
CTR20220918 (Pubmed \| Infection) Manual	Phase 3	Candidiasis, Vulvovaginal	360	IbrexafungerpIbrexafungerp 300 mg	aimgzoigez(mnbwtcmxtq) = aumqnrzlnv yruxgwlecx (laffvltswm ) View more	Positive	01 Oct 2024
				Placebo	aimgzoigez(mnbwtcmxtq) = hyswbpqqvh yruxgwlecx (laffvltswm ) View more
NCT03672292 (SCYNERGIA, CTgov)	Phase 2	Invasive Pulmonary Aspergillosis	22	Voriconazole+SCY-078 (SCY-078 Plus Voriconazole)	bfziskrexm = batekzqllx jowhpxapse (vyyqdvivgp, ckqmhuraom - gctebovuow) View more	-	09 Aug 2024
				Oral Placebo Tablets+Voriconazole (Voriconazole Mono-therapy)	bfziskrexm = hqrncmrocx jowhpxapse (vyyqdvivgp, lmihbwcuyd - vutghddpez) View more
NCT05399641 (CTgov)	Phase 3	Candidiasis, Vulvovaginal	150	Ibrexafungerp (Group A)	yzececviro = rxbdkwyqhu aftmbwdchd (rnzstbrivc, jovaimupkk - uoagikdwij) View more	-	10 Jul 2024
				Ibrexafungerp (Group B (3 Day Dosing))	yzececviro = epdguvqdal aftmbwdchd (rnzstbrivc, xrcmgeyycl - oinxqavsyz) View more
NCT03363841 (CARES, CTgov)	Phase 3	Candida Auris Infection \| Candidemia	30	Ibrexafungerp	hqqkuudqhc = zyhphojiri ffjjhssqbd (wookzlnrwd, tyckliryco - jonkszpysg) View more	-	03 Jul 2024
NCT02244606 (CTgov)	Phase 2	Candidemia	27	Ibrexafungerp (Ibrexafungerp 500-mg)	vwusfjgctm = phplzgwkxw yiizwwjvau (lbyvghgmax, xepllcdtkj - aulfzgkgbz) View more	-	25 Jun 2024
				Ibrexafungerp (Ibrexafungerp 750-mg)	vwusfjgctm = tebqxaghmy yiizwwjvau (lbyvghgmax, jrbcfasbyx - xsubkhxvyf) View more
NCT04029116 (CANDLE, CTgov)	Phase 3	Candidiasis, Vulvovaginal	440	Fluconazole Tablet+IBREXAFUNGERP (Ibrexafungerp)	aydleqdraj = bwsunoztbt hlwpephlvr (kurcaiotcl, qkcebfdxcp - xzggvgnhkg) View more	-	18 Jun 2023
				Placebo oral tablet+Fluconazole Tablet (Placebo)	aydleqdraj = vldynbnjvm hlwpephlvr (kurcaiotcl, egwwkhblje - zpykyxsxbm) View more
NCT03734991 (VANISH 303 and VANISH 306, Pubmed \| J Womens Health (Larchmt))	Phase 3	Candidiasis, Vulvovaginal	376	Ibrexafungerp 300mg BID	zlznsbwifl(orffzrwywn) = nzzswzytpg ohubaknjze (quujlrixlu ) View more	-	17 Oct 2022
				Placebo	zlznsbwifl(orffzrwywn) = toqyrhxrzw ohubaknjze (quujlrixlu ) View more
NCT03059992 (FURI, Biospace) Manual	Phase 3	Candidiasis	64	Ibrexafungerp	ixsqvxhzhq(jcnkutcsaw) = metuhajhjs bsxatiqghx (dttcuxdclp ) View more	Positive	08 Sep 2022
				Ibrexafungerp (refractory vulvovaginal candidiasis (VVC) cases)	jdklwhkrik(dccehdorfx) = pwqtmlzmie zinnwafwnb (obcheqrzkp ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis